Literature DB >> 3929677

Comparative in vitro inhibitory and killing activity of cefpirome, ceftazidime, and cefotaxime against Pseudomonas aeruginosa, enterococci, Staphylococcus epidermidis, and methicillin-susceptible and -resistant and tolerant and nontolerant Staphylococcus aureus.

E J Goldstein, D M Citron.   

Abstract

With a macrotube dilution method, MICs and MBCs were determined for three aminothiazolyl cephalosporins, cefpirome (HR 810), ceftazidime, and cefotaxime, against Pseudomonas aeruginosa, enterococci, Staphylococcus epidermidis, and methicillin-resistant, -susceptible, and -tolerant strains of Staphylococcus aureus. Comparatively, cefpirome was the most active agent against all gram-positive cocci, including enterococci and methicillin-resistant S. aureus, and was as active as ceftazidime against P. aeruginosa. MBCs of cefpirome were within two dilutions of the MICs for 91% of P. aeruginosa and 90% of gram-positive cocci strains tested, except methicillin-resistant S. aureus, for which the MBCs were within three dilutions for 90% of strains.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3929677      PMCID: PMC176333          DOI: 10.1128/AAC.28.1.160

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Enterococcal sensitivity to third generation cephalosporins.

Authors:  T M File; J S Tan
Journal:  Lancet       Date:  1981-08-29       Impact factor: 79.321

2.  Ceftazidime as a single agent in the treatment of severe Pseudomonas aeruginosa infections.

Authors:  N Clumeck; B Gordts; I Dab; N Jaspar; Y Van Laethem; J P Butzler
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

3.  The clinical significance of tolerance of Staphylococcus aureus.

Authors:  D Kaye
Journal:  Ann Intern Med       Date:  1980-12       Impact factor: 25.391

4.  Resistance of methicillin-resistant staphylococcus aureus to third-generation cephalosporins.

Authors:  J K Collins; J T Mader; M T Kelly
Journal:  J Infect Dis       Date:  1983-03       Impact factor: 5.226

Review 5.  Cefotaxime: a review of in vitro antimicrobial properties and spectrum of activity.

Authors:  R N Jones; C Thornsberry
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct

6.  In vitro evaluation of HR810, a new wide-spectrum aminothiazolyl alpha-methoxyimino cephalosporin.

Authors:  R N Jones; C Thornsberry; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

7.  Treatment of infections due to methicillin-resistant Staphylococcus aureus.

Authors:  C Watanakunakorn
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

8.  The emergence of methicillin-resistant Staphylococcus aureus infections in United States hospitals. Possible role of the house staff-patient transfer circuit.

Authors:  R W Haley; A W Hightower; R F Khabbaz; C Thornsberry; W J Martone; J R Allen; J M Hughes
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

9.  Ceftazidime: aspects of efficacy and tolerance.

Authors:  R D Foord
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

10.  Early results of a comparative trial of ceftazidime versus cephalothin, carbenicillin and gentamicin in the treatment of febrile granulocytopenic patients.

Authors:  R Ramphal; B S Kramer; K H Rand; R S Weiner; J W Shands
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

View more
  6 in total

Review 1.  Drug treatment of pneumonia in the elderly: efficacy and costs.

Authors:  E Saltiel; S Weingarten
Journal:  Pharmacoeconomics       Date:  1993-04       Impact factor: 4.981

2.  Evaluation of two methods for overcoming the antibiotic carry-over effect.

Authors:  R H Eng; S M Smith; C E Cherubin; E N Tan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-01       Impact factor: 3.267

Review 3.  Nursing home-acquired pneumonia. Treatment options.

Authors:  T J Marrie; K L Slayter
Journal:  Drugs Aging       Date:  1996-05       Impact factor: 3.923

Review 4.  Susceptibility of enterococci and epidemiology of enterococcal infection in the 1980s.

Authors:  R C George; A H Uttley
Journal:  Epidemiol Infect       Date:  1989-12       Impact factor: 2.451

5.  Activity of cefpirome combined with beta-lactamase inhibitors and affinity for the penicillin-binding proteins of methicillin-resistant Staphylococcus aureus.

Authors:  L J Piddock; E A Traynor; D J Griggs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-04       Impact factor: 3.267

Review 6.  Cefpirome clinical pharmacokinetics.

Authors:  L C Strenkoski; D E Nix
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.